Differential effects of the KRAS gene on recurrence in right- vs left-sided colorectal liver metastases undergoing radiofrequency ablation

Table 2 Recurrence after colorectal liver metastases underwent radiofrequency ablation, n (%)

Characteristic	All patients (n = 164)	Right colon			Left colon
		Wild (n = 9)	Mutation (n = 18)	P value	Wild (n = 80)	Mutation (n = 57)	P value
Intrahepatic recurrence	101 (61.6)	5 (55.6)	10 (55.6)	1.000	42 (52.5)	44 (77.2)	0.003
Extrahepatic recurrence	88 (53.7)	5 (55.6)	7 (38.9)	0.448	43 (53.7)	33 (57.9)	0.630
Number				1.000			0.460
Single	79 (89.8)	4 (80.0)	6 (85.7)		40 (93.0)	29 (87.9)
Multiple	9 (10.2)	1 (20.0)	1 (14.3)		3 (7.0)	4 (12.1)
Site of single extrahepatic recurrence
Lung	38 (48.1)	2 (50.0)	2 (33.3)	0.582	20 (50.0)	14 (48.3)	1.000
Bone	11 (13.9)	0	2 (33.3)	0.538	5 (10.0)	4 (13.8)	1.000
Peritoneal	8 (10.1)	0	0	-	4 (8.0)	4 (13.8)	0.719
Ovary	4 (5.1)	1 (25.0)	0	0.333	2 (4.0)	1 (3.4)	1.000
Adrenal	2 (2.5)	0	0	-	0	2 (6.9)	0.171
Lymph node	15 (19.0)	1 (25.0)	2 (33.3)	1.000	8 (16.0)	4 (13.8)	0.761
Other	1 (1.3)	0	0	-	1 (2.0)	0	1.000
RFS1	10 (0-57)	11 (1-35)	14 (1-45)	0.944	11 (0-57)	9 (0-44)	0.012
Intrahepatic RFS1	19 (0-86)	13 (1-35)	15 (1-49)	0.950	25 (0-86)	15 (0-63)	0.007
Extrahepatic RFS1	23 (0-95)	22 (2-35)	37 (1-47)	0.515	27 (0-57)	22 (0-95)	0.467

¹Data are medians, with ranges in parentheses. Unless indicated otherwise, data indicates the number of patients, with percentages in parentheses.

RFS: Recurrence-free survival.